4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
18 nov. 2024 08h00 HE
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and...
4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy
18 nov. 2024 02h00 HE
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Trogenix Unveils Revolutionary Platform to Transform Cancer Treatment Through Precision Viral Immunotherapy Company founded by 4BIO Capital and...
4BIO Capital Strengthens Advisory Board and Investment Team
11 mars 2024 10h00 HE
|
4Bio Capital
Press Release 4BIO Capital Strengthens Advisory Board and Investment Team Industry veteran and former CEO of Vifor Pharma Abbas Hussain and world leading vectorology expert and LogicBio...
Development Bank of Japan invests in 4BIO Capital’s Ventures III fund
04 janv. 2024 07h00 HE
|
4Bio Capital
Press Release Development Bank of Japan invests in 4BIO Capital’s Ventures III fund 4BIO Ventures III targeting $200-300 million to unlock the treatments of the future by investing in advanced...
Development Bank of Japan invests in 4BIO Capital’s Ventures III fund
04 janv. 2024 02h00 HE
|
4Bio Capital
Press Release Development Bank of Japan invests in 4BIO Capital’s Ventures III fund 4BIO Ventures III targeting $200-300 million to unlock the treatments of the future by investing in advanced...
4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
10 janv. 2022 13h00 HE
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology Collaboration will combine...
4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology
10 janv. 2022 13h00 HE
|
4Bio Capital
Press Release 4BIO Capital Portfolio Company Carisma to Collaborate with Moderna to Develop in vivo Engineered Chimeric Antigen Receptor Monocytes (CAR-M) for Oncology Collaboration will combine...